AstraZeneca (AZN) Shares Fall 7% Amid Reports of $400 Billion Merger Talks with Bristol Myers Squibb (BMY)
AstraZeneca's shares fell by 7% following reports of ongoing merger talks with Bristol Myers Squibb, potentially valuing the deal at around $400 billion. This significant drop reflects investor concerns about the implications of such a large merger in the pharmaceutical sector.